Press Releases for INO

Press Releases
RidgewaterEquity.com Free Fundamental Sector & Market Research on FNM, KGC, HCN, SD, MVL and INO
Inovio Biomedical and NIH Vaccine Research Center Sign Research Collaboration Agreement to Develop Universal Influenza Vaccines
First Human Demonstration of Significant, Persistent Antibody Response Using Electroporation-Delivered DNA Vaccine Published in Human Gene Therapy
Inovio Closes $30 Million Registered Direct Offering
Inovio Announces $30 Million Registered Direct Offering
Inovio Biomedical Universal Influenza Vaccines Demonstrate 100% Protection Against Current Pandemic A/H1N1 Influenza Viruses in Animal Studies
Inovio Biomedical Universal Dengue DNA Vaccine Demonstrates Strong Immune Responses Against All Four Serotypes
Inovio Biomedical to Present at Jesup & Lamont Growth Stock Conference
Inovio Biomedical H1N1 Influenza DNA Vaccines Demonstrate 100% Responses Against Swine Flu in Vaccinated Pigs
Inovio Biomedical to Present at International DNA Vaccine Conference
Inovio Biomedical, National Microbiology Laboratory, and University of Pennsylvania to Evaluate Candidate DNA Vaccines against “Swine” Influenza A (H1N1)
Vaccine Pioneer Joins Inovio Biomedical’s Scientific Advisory Board
Inovio Biomedical Grants Option for Intravascular Applications of its Electroporation Technology to Cardigant Medical
Inovio Biomedical to Present at 8th Annual Needham Life Sciences Conference
Inovio Biomedical Influenza DNA Vaccines Demonstrate Potential to Protect Against Newly Emerging Flu Strains with Pandemic Potential
Inovio Biomedical Closes Merger with VGX Pharmaceuticals to Form a Leading Vaccine Discovery, Development and Delivery Company
Inovio Biomedical and VGX Pharmaceuticals Stockholders Overwhelmingly Approve Proposed Merger
Inovio Biomedical Reports First Quarter 2009 Financial Results
Inovio Biomedical’s Registration Statement in Connection with Proposed Merger with VGX Pharmaceuticals Declared Effective
Ng Tee Khiang Appointed to Inovio Biomedical's Board of Directors
Ng Tee Khiang Appointed to Inovio Biomedical’s Board of Directors
Inovio Biomedical Reports 4(th) Quarter and Year-End 2008 Financial Results
Inovio Biomedical and VGX Pharmaceuticals Extend Completion Date for Definitive Merger Agreement
Director Resigns from Inovio Biomedical’s Board
Inovio Biomedical’s Advances in Electroporation-Delivered Therapeutic Vaccines Presented at International DNA Vaccine Conference
Inovio Biomedical and VGX Pharmaceuticals Amend Merger Agreement
Chin-Cheong Chong Elected to Inovio Biomedical’s Board of Directors
CORRECTING and REPLACING Inovio Biomedical and VGX Pharmaceuticals to Highlight Recent Advances in Electroporation-Delivered DNA Vaccines at International DNA Vaccines Conference
Inovio Biomedical and VGX Pharmaceuticals to Highlight Recent Advances in Electroporation-Delivered DVA Vaccines at International DNA Vaccines Conference
First-Ever Human Trial of DNA-Based Immunotherapy Delivered Using Inovio Biomedical’s Electroporation Technology Shows Safety and Durable Systemic Clinical Response
Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7%
DNA Vaccine Company Inovio Biomedical Reports Third Quarter 2008 Financial Results
FINAL ANNOUNCEMENT: Medtech Insight/Windhover's Medical Device Investor Day Symposium and Investment In Innovation (In3) East Conference -- October 22-24, Boston, MA
Inovio Awarded US Army Contract for Bio-Defense Vaccine Research Using its Electroporation Delivery Technology
Inovio Biomedical Achieves 75% Complete Response Rate in Preclinical Testing of DNA-Based Cancer Vaccine Using Its Electroporation DNA Delivery System
Inovio Biomedical Expands In Vivo Electroporation License with International AIDS Vaccine Initiative for HIV Vaccine Research
Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results
Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
Inovio Biomedical's First Proprietary DNA Vaccine Achieves 100% Protection Against Avian Flu in Pre-Clinical Testing
Inovio Biomedical to Highlight Electroporation-Based DNA Vaccine Delivery at Scientific Conferences
Inovio Biomedical and VGX Pharmaceuticals Sign Merger Agreement
Early Results from Ongoing Clinical Study of Hepatitis C Vaccine Delivered by Inovio Biomedical's Electroporation System Show Increased T-Cell Responses and Reduced Viral Loads
Therapeutic DNA Vaccine Company Inovio Biomedical Presenting at BIO International
Inovio Biomedical Provides Updated Interim Data on Phase I/II Clinical Study of Electroporation-Delivered Prostate Cancer DNA Vaccine at ASGT Annual Meeting
Reduced Hepatitis C Viral Level Achieved with DNA Vaccine Delivered by Inovio Biomedical's Electroporation Delivery System in Phase I/II Clinical Study
Inovio Biomedical Licenses Electroporation Delivery Technology to Leading U.S. Government Contractor, Advanced BioScience Laboratories, Inc.
Therapeutic DNA Vaccine Company Inovio Biomedical to Present at Upcoming Scientific Conferences - May 27 2008 12:58AM
Therapeutic DNA Vaccine Company Inovio Biomedical Reports First Quarter 2008 Financial Results - May 27 2008 1:40AM
Patrick Gan Elected to Inovio Biomedical Board of Directors - May 27 2008 1:38AM
Therapeutic Vaccine Company Inovio Biomedical Demonstrates Utility of Its Electroporation Delivery Technology as Potent Vaccine Adjuvant
Prostate Cancer DNA Vaccine Results in Higher T-Cell Response When Delivered via Inovio Biomedical's Electroporation Delivery System
Vical Begins Phase 1 Trial of Gene-Based IL-2 With Inovio Electroporation Technology